New hope for pregnant women: drug may stop CMV in unborn babies

NCT ID NCT05446571

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug letermovir can stop cytomegalovirus (CMV) in unborn babies better than the current treatment valaciclovir. Pregnant women with a CMV-infected fetus will take one of the two drugs daily until delivery. The goal is to see if letermovir leads to a negative CMV test in the baby's blood at birth, which could mean fewer health problems later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: letermovir and valaciclovir
What this could lead to: If letermovir works better, it could offer a more effective prenatal treatment to prevent CMV-related birth defects and long-term health problems.
What could go wrong: This is a small, early-stage trial with only 46 participants, so results may not apply to everyone. Both drugs have side effects, and the study is still recruiting, so it's too soon to know if letermovir is truly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV INFECTED FETUSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fetal cytomegalovirus syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV INFECTED FETUSES PREGNANT WOMEN

Contacts and locations

Locations

Hopital Necker - Enfants malades
RECRUITING

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.